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Objective: To investigate the relationship between genetic factor and prostate cancer
(Pca) risk and the possible cause in it.
Methods: The polymorphisms of cytochrome P450 family 17 (CYPl7) rs743572, p27
V109G and androgen receptor (AR) gene CAG repeat length in peripheral blood from 70
cases and 70 controls were detected through the polymerase chain reaction-restriction
fragment length polymorphism technique or short tandem repeat-polymerase chain re-
action technique. Then, according to the results of case–control study, the recombinant
plasmids containing the wild/mutant p27 gene were constructed and transfected Pca
LNcap cells. After 24 and 72 h of transfection, the cell proliferative activity was deter-
mined by MTT method, cell cycle distribution and apoptosis was detected by ﬂow
cytometry, and the expression level of bcl-2, caspase-3 and p27 protein was determined
by Western-blot.
Results: In three target polymorphisms, only p27 V109G polymorphism was related to
Pca risk (P = 0.030, OR = 0.202, 95% CI = 0.042–0.973). Pca risk of p27-109G allele
was lower than −109V allele (P = 0.006, OR = 0.285, 95% CI = 0.110–0.737). Cells
transfected with wild/mutant p27 gene both showed the higher cells apoptosis rate and the
lower cell proliferative activity than mock cells (P < 0.05 or 0.01), the regulatory effect of
mutant p27 on cell proliferation and apoptosis was stronger than the wild p27 (P < 0.05).
Conclusions: p27-109G allele that could cause higher p27 protein expression
than −109V allele in LNcap cells, maybe is the protective factor of Pca.1. Introduction
As a common urological malignancy, thousands of studies
related to prostate cancer (Pca) are reported every year. It is
known that the only established risk factors of Pca are age,
ethnicity and family history of Pca [1]. And numerous studies
have conﬁrmed that genetic factor is one the main causes of
high incidence of Pca [2,3]. Therefore, it is important for
understanding the effect of genetic polymorphisms in people
of different ethnic backgrounds.
In many large-scale and genome-wide genetic studies, single
nucleotide polymorphisms (SNPs) have been found to be asso-
ciated with the increased risk of Pca [4,5]. Cytochrome P450family 17 (CYPl7) rs743572 is the MspA1 polymorphism
(T/C) in 50-promotor region at 34 base pair upstream of the
initiation of translation, A1 (wild allele) and A2 (variant
allele) are the alleles. Published data on the association
between rs743572 polymorphism and risk of Pca showed
inconclusive results [6]. For example, Haiman et al. found that
A2 allele could increase the efﬁciency of transcription, then
the androgen synthesis was elevated and consequently the risk
of Pca was raised [7], but Wadelius and Habuchi reported that
A1 allele may increase the risk of Pca [8,9]. P27 is a key
regulator of the progression from G1 to S phase of the cell
cycle and acts by binding and inhibiting the Cyclin E-CDK2
complex in the G1 phase [10]. P27 V109G polymorphism had
been suggested to confer the risk of advanced Pca in
Caucasian males, but a hospital-based case–control study re-
ported that there was no signiﬁcant association between p27
V109G polymorphism and Pca risk [11]. The androgen receptor
(AR) plays a central role in the normal development of the
prostate gland, in prostate carcinogenesis, and in ther the CC BY-NC-ND
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repeat length polymorphism exists in the ﬁrst exon of AR gene,
and it varies in different races or populations, such as 23–25
repeats in the Hispanic population, 21–22 in the Caucasian
population and the shortest average CAG repeats (19–20) in
the black population [13,14]. The variations of CAG repeat
length suggest that shorter CAG repeat lenghs, which are
known to be associated with higher AR activity, may be
associated with higher Pca risk [15].
In the study, we explored the relationship between the
polymorphisms in CYP17, p27 and AR gene and the risk of Pca
in Chinese men. And then, through transfecting the recombinant
plasmids containing wild/mutant target gene, we tried to inves-
tigate the possible causes of polymorphism which inﬂuence Pca
risk in vitro.
2. Materials and methods
2.1. Subjects
The case group was the local hospitalized patients with Pca
diagnosed by histopathology after 2008. The patients in control
group were those without tumors selected from Digestive Sys-
tem Department, Respiratory Department and Otorhinolaryn-
gology Department of the same hospital. All the subjects were
enrolled from People's Hospital of Zhengzhou. The matching
condition was as follows: the same age group, the same na-
tionality (Han) and the same type of residence. The control was
the patients with other diseases, excluding the diseases of uri-
nary system and endocrine system, coronary artery disease and
malignant tumors. The base characteristics of both groups were
similar.
2.2. Blood collection and extraction of DNA in plasma
After informed consent, 3 mL peripheral venous blood of all
the subjects was collected. Then, EDTA was added for anti-
coagulating, the plasma and erythrocytes were separated and
placed in −80 C fridge. After that, the plasma DNA was
extracted, the polymorphisms of p27 V109G and rs743572 in
CYP17 gene were detected by the polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) tech-
nique. AR gene CAG repeat length was detected by short tandem
repeat-polymerase chain reaction technique.
The authors state that the protocol for the research project had
been approved by the Ethical Committee of the Medical Ethics
Committee of People's Hospital of Zhengzhou. Before the study,
the purpose and procedures of the surveys were explained to all
the participants, and a written informed consent was obtained
from each participant.Table 1
PCR primers sequences.
Gene PCR primer (50/30)
CYP17 50-CATTCGCACTCTGGAGTC-30
50-AGGCTCTTGGGGTACTTG-30
AR 50-6-FAM-TCCAGAATCTGTTCCAGAGCGTGC
50-GCTGTGAAGGTTGCTGTTCCTCAT-30
p27 50-TGCAGACCCGGGAGAAAG-30
50-CCGCTAACCCCGTCTGG-302.3. PCR primers and reaction condition
The primers of CYP17, p27 and AR gene were designed by
using Primer Premier 5 software. The sequences of primers
were seen in Table 1 and they were synthesized by Shanghai
Sangon Biotechnology co., Ltd. The CYP17 PCR procedures
were as follows: an initial denaturation step at 93 C for 2 min,
followed by an ampliﬁcation step for 35 cycles at 93 C for
30 s, 58 C for 30 s and 72 C for 30 s, and followed by a ﬁnal
extension step at 72 C for 10 min. The PCR products were
digested with restriction enzyme MspAⅡ (Promega Corp.,
USA) and separated by 3% agarose gel electrophoresis. The A1
genotype is identiﬁed by the presence of 414 bp, A1/A2 ge-
notype by 414, 290, 124 bp and the A2 genotype by 290 and
124 bp.
AR gene PCR procedures were as follows: an initial dena-
turation step at 95 C for 10 min, followed by an ampliﬁcation
step for 35 cycles at 94 C for 30 s, 60 C for 30 s and 72 C for
45 s, and followed by a ﬁnal extension step at 72 C for 10 min.
The PCR products were separated by agarose gel electropho-
resis. After the electrophoresis, the DNA was detected by ABI
PRISM 3770 sequencer and the data was analyzed by GeneScan
Analysis 3.7 and Genotyper 3.7 software for identifying the
genotype.
P27 gene PCR procedures were as follows: an initial
denaturation step at 94 C for 5 min, followed by an ampliﬁ-
cation step for 35 cycles at 94 C for 45 s, 60 C for 30 s and
72 C for 60 s, and followed by a ﬁnal extension step at 72 C
for 10 min. The PCR products were digested with the restric-
tion enzyme Bgl Ⅰ (New England BioLabs Inc, USA). The V/V
genotype is identiﬁed by the presence of 76, 378 bp, V/G
genotype by 76, 113, 265, 378 bp and the G/G genotype by 76,
113 and 265 bp.
2.4. Construction of the recombinant plasmids
containing p27 gene
In order to obtain the mutant p27 gene, the pcDNA3.1-p27
(V/V) was set as the template, the primers were as follows: F-50-
GCAGGAGAGCCAGGATGGCAGCGGGAGCCGCCCG-30,
and R-50-CGGGCGGCTCCCGCTGCCATCCTGGCTCTCC-
TGC-30. PCR procedures were as follows: an initial denaturation
step at 95 C for 1 min, followed by an ampliﬁcation step for 18
cycles at 95 C for 45 s, 60 C for 60 s and 68 C for 7 min, and
followed by a ﬁnal extension step at 72 C for 10 min. After the
reaction, 1 mL Dpn I restriction enzyme was added into the PCR
reaction system, mixed and incubated for 1 h. After the diges-
tion, the products were used for transforming and cloning.
Finally, the plasmid containing the correct sequence was named
pcDNA3.1-p27 (G/G).Annealing temperature Length (bp)
58 414
-30 60 (CAG)n
60 454
Table 2
Univariate analysis of the relationship of the polymorphisms and Pca risk.
Genotypes Case Control OR value 95% CI P value
CYP17 rs743572
A1/A1 10 15 1.000
A1/A2 37 38 1.461 0.582–3.662 0.418
A2/A2 23 17 2.029 0.734–5.608 0.170
Allele frequency of CYP17 rs743572
A1 57 68 1.000
A2 83 72 1.375 0.857–2.207 0.186
AR gene (CAG)n
18 36 40 1.000
>18 34 30 1.259 0.647–2.451 0.497
p27 V109G
V/V 66 60 1.000
V/G 2 1 1.818 0.161–20.566 0.624
G/G 2 9 0.202 0.042–0.973 0.030
Allele frequency of p27
V 134 121 1.000
G 6 19 0.285 0.110–0.737 0.006
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The pcDNA3.1-p27(G/G), pcDNA3.1-p27(V/V) and null
vector pcDNA3.1 was respectively transfected the LNcap cells
in 96-well plate, and the transfected cells were grouped as the
p27 G-allele cells, p27 V-allele cells and mock cells, respec-
tively. The cell proliferative activity was determined by MTT
method after 24, 48 and 72 h of transfection. The untreated cells
were regarded as blank cells, the OD value at 490 nm repre-
sented the proliferative activity.
Cell cycle and apoptosis rate were determined by using ﬂow
cytometry. LNcap cells were seeded in 6-well plate at 1 × 106
cells/mL and transfected according to the above method. After
24 or 72 h of transfection, cells were collected and ﬁxed with
70% ethanol for 48 h at 4 C, rehydrated by ice-cold PBS, and
stained by 50 mg/mL propidium iodide (PI). The percentage of
cells in each cell cycle phase was analyzed by Elite ﬂow cy-
tometer (Coulter Cytometry, Inc., USA). Similarly, the cell
apoptosis rate at different time points (24, 48 and 72 h post-
transfection) was also detected.
2.6. Expression levels of apoptosis-related proteins
LNcap cells were collected after 24, 72 h of the transfection,
then the RIPI lysis buffer was added. b-actin served as the
endogenous control, the expression level of bcl-2, caspase-3 and
p27 was semiquantitatively analyzed by Western-blot. Anti-
bodies to bcl-2, caspase-3, p27 and b-actin as well as HRP-
labeled secondary anti-rabbit antibodies were obtained from
Abcam Co., UK.
2.7. Statistical analysis
The results were analyzed by SPSS 16.0 software. Differ-
ences in genotype frequency distribution between case and
control group was done by using c2 test. Comparisons among
multiple groups were analyzed by One-way ANOVA. Post hoc
analysis was carried out, whenever appropriate, by the Bonfer-
roni test. All the experiments in vitro repeated at least three
times. When P < 0.05, the difference was considered to be
statistically signiﬁcant.
3. Results
3.1. Relationship between polymorphisms and Pca risk
Polymorphisms of CYP17 rs743572 and AR gene CAG
sequence repeat were not associated with Pca risk, only p27
V109G polymorphism was related to it (P < 0.05). Compared
with the p27 V/V genotype carriers, the G/G genotype carriers
showed the lower Pca risk (P = 0.030, OR = 0.202, 95%
CI = 0.042–0.973); and −109G allele could reduce Pca risk
(P = 0.006, OR = 0.285, 95% CI = 0.110–0.737) (Table 2).
3.2. Inﬂuence of p27 V109G polymorphism on LNcap
cell proliferative activity, cell cycle distribution and
apoptosis
Figure 1 showed that the cell proliferative activity of V-allele
cells and G-allele cells were both lower than mock cells after
48 h of transfection (P < 0.05 or 0.01). Moreover, the cellproliferative activity of p27 G-allele cells was lower than V-
allele cells 72 h post-transfection (P < 0.05). Cell cycle analysis
(Table 3) showed that transfection with recombinant plasmids
could cause obvious G0/G1 cell cycle arrest. In p27 V-allele and
G-allele cells, signiﬁcantly higher number of cells was in G0/G1
stage as well as signiﬁcantly lower number of cells in S and G2/
M stages, as compared to the mock cells (P < 0.05 or 0.01);
compared with the p27 V-allele cells, the p27 G-allele cells
manifested signiﬁcantly higher number of cells in G0/G1 stage as
well as signiﬁcantly lower number of cells in S stage after 72 h
of transfection (P < 0.05).
Similarly, the apoptosis rate of V-allele cells and G-allele
cells were both obviously higher than mock cells since 24 h of
transfection (P < 0.01), and that of G-allele cells was also lower
than V-allele cells since 24 h of transfection (P < 0.05).
3.3. Inﬂuence of p27 V109G polymorphism on the
expression of bcl-2, caspase-3 and p27 protein
Results in Figure 2 showed that transfection with wild and
mutant p27 gene both could down-regulate bcl-2 expression and
up-regulate the expression of caspase-3 and p27, and this reg-
ulatory effect caused by G-allele was more obvious than that
caused by V-allele (P < 0.05 or 0.01).
4. Discussion
In the study, through the case–control study, we found that
only p27 V109G polymorphism was related to Pca risk, and p27
G/G genotype could reduce the risk. Based on these results, in
vitro, we found cells transfected with p27 G-allele displayed a
lower proliferative activity and expression level of caspase-3 and
p27 protein and a higher apoptosis rate than cells transfected
with V-allele, though cells transfected with mutant and wild p27
gene both manifested lower proliferative activity and higher
apoptosis rate than the mock cells.
Several clinical studies and laboratory experiments have
demonstrated that p27 is an important tumor suppressor gene in
Pca etiology. Huang et al. detected the p27 V109G poly-
morphism in 190 Pca patients and 292 controls, their ﬁndings
showed there was no difference of G allele frequency between
the case and control group; in general, they believed p27 V109G
Figure 1. Determination of LNcap cells proliferative activity and apoptosis rate by MTT assay and ﬂow cytometry.
Note: *Compared with mock cells, P < 0.05; **compared with mock cells, P < 0.01; #compared with p27 V-allele cells, P < 0.05.
Table 3
Cell cycle distribution after 24 or 72 h of transfection (%).
Groups 24 h Post-transfection 72 h Post-transfection
G0/G1 S G2/M G0/G1 S G2/M
LNcap cells 68.50 ± 1.65 20.66 ± 1.03 10.84 ± 0.96 67.39 ± 1.64 21.54 ± 1.22 11.07 ± 0.88
Mock cells 69.44 ± 1.78 20.17 ± 0.85 10.42 ± 0.75 67.58 ± 1.95 21.63 ± 1.35 10.79 ± 0.68
p27 V-allele cells 74.78 ± 1.57* 16.97 ± 0.69** 8.45 ± 0.71* 80.47 ± 1.82** 13.42 ± 0.84** 6.11 ± 0.75**
p27 G-allele cells 75.61 ± 2.03* 16.08 ± 0.91** 8.32 ± 0.59* 85.42 ± 2.46**# 10.08 ± 0.91**# 4.50 ± 0.73**
Note: *Compared with Mock cells, P < 0.05; **Compared with Mock cells, P < 0.01; #Compared with p27 V-allele cells, P < 0.05.
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[11]. Chang et al. conducted a family-based test and their subjects
were hereditary prostate cancer probands and their family
members, they found the C allele of −79C/T was over trans-
mitted from parents to their affected offspring and evidence for
this association was primarily contributed by affected offspring
whose age at diagnosis was <65 years [16]. Another study in
which the subjects were European-American population was
similar to the present study about the results, they pointed that
the p27 genotype VV was associated with an increased risk of
advanced Pca (OR, 1.95; 95% CI, 1.09–3.47) [17]. In the aboveFigure 2. Semiquantitative analysis of p27, bcl-2 and caspase-3 protein exprestudies, their results were not usually in keeping with this study,
which may be attributed to the hereditary heterogeneity of
subjects, different polymorphisms of p27 gene and so on.
Moreover, the sample size possibly inﬂuenced the results.
Currently, the reports about the relationship between this
polymorphism and Pca risk were contradictory. For example,
Sekiya reported that the common polymorphism rs2066827 may
play a role in corticotropinoma susceptibility and tumorigenesis
through a molecular mechanism not fully understood thus far
[18]. The results of a case–control study showed that the GG
genotype of p27 V109G polymorphism was signiﬁcantlyssion.
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(P = 0.02) [19]. In our study, mutant p27 protein expression
was higher than the wild, therefore, the effect on accelerating
cell apoptosis of mutant p27 was more obvious.
However, because the incidence of Pca was quite low in
Chinese population, the cases collected in the last three years
were still not enough, which may affect the performance sta-
tistics and the reliability of the results.
In summary, we proved that p27-109G allele was the pro-
tective factor of Pca. Mutant p27 protein could more obviously
promote Pca LNcap cell apoptosis than the wild, which may be
caused by the higher expression level of mutant p27 protein than
the wild protein.
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